Literature DB >> 3110508

The spectrum of IgM monoclonal gammopathy in 430 cases.

R A Kyle, J P Garton.   

Abstract

IgM monoclonal gammopathy consists of a broad spectrum of diseases, ranging from apparently benign to malignant conditions. In a long-term follow-up study of 430 patients in whom a monoclonal IgM serum protein had been identified, 242 (56%) had monoclonal gammopathy of undetermined significance, 71 (17%) had Waldenström's macroglobulinemia, 28 (7%) had lymphoma, 21 (5%) had chronic lymphocytic leukemia, 6 (1%) had primary amyloidosis, and 62 (14%) had other malignant lymphoproliferative diseases. More than two-thirds of the patients died, and the most common cause of death was a lymphoid malignant process. Almost a fifth of the patients with an apparently benign monoclonal gammopathy subsequently had a lymphoid malignant lesion (in one patient, more than 20 years after the detection of the serum M protein). The median duration of time from the recognition of the M protein until the development of a malignant lymphoid disease ranged from 4 to 9 years. An increased number of lymphocytes or plasma cells on bone marrow examination was not a reliable indicator of the likelihood of such an outcome. Thus, follow-up of these patients should be conducted indefinitely.

Entities:  

Mesh:

Substances:

Year:  1987        PMID: 3110508     DOI: 10.1016/s0025-6196(12)65225-2

Source DB:  PubMed          Journal:  Mayo Clin Proc        ISSN: 0025-6196            Impact factor:   7.616


  18 in total

1.  [Polyneuropathies in monoclonal gammopathy of undetermined significance: initial manifestation of a lymphoma].

Authors:  C Drees; M Grond; B Szelies; M Dietlein; B Salzberger; V Diehl; W D Heiss
Journal:  Med Klin (Munich)       Date:  1997-02-15

2.  Robert Arthur Kyle, MD: a conversation with the editor.

Authors:  Robert Arthur Kyle; William Clifford Roberts
Journal:  Proc (Bayl Univ Med Cent)       Date:  2010-10

3.  Lymphoma, paraproteinaemia, and neuropathy.

Authors:  J H Wokke; J H Morris; M Donaghy
Journal:  J Neurol Neurosurg Psychiatry       Date:  1996-06       Impact factor: 10.154

4.  A 72-year old man with low-grade non-Hodgkin's lymphoma, cold agglutinin hemolysis, rapidly progressive jaundice, hepatomegaly, and dyspnea.

Authors:  R W van der Hulst; J C Kluin-Nelemans; R Bieger; A Brand
Journal:  Ann Hematol       Date:  1993-11       Impact factor: 3.673

5.  Human monoclonal antibodies reactive to oligodendrocytes promote remyelination in a model of multiple sclerosis.

Authors:  A E Warrington; K Asakura; A J Bieber; B Ciric; V Van Keulen; S V Kaveri; R A Kyle; L R Pease; M Rodriguez
Journal:  Proc Natl Acad Sci U S A       Date:  2000-06-06       Impact factor: 11.205

Review 6.  Immunoglobulin m monoclonal gammopathy of undetermined significance and smoldering Waldenström macroglobulinemia.

Authors:  Robert A Kyle; Terry M Therneau; Angela Dispenzieri; Shaji Kumar; Joanne T Benson; Dirk R Larson; L Joseph Melton; S Vincent Rajkumar
Journal:  Clin Lymphoma Myeloma Leuk       Date:  2013-03-13

Review 7.  Heavy chain disease.

Authors:  Thomas E Witzig; Dietlind L Wahner-Roedler
Journal:  Curr Treat Options Oncol       Date:  2002-06

8.  IgM multiple myeloma: a diagnostic challenge in a patient with coexisting chronic lymphocytic leukaemia.

Authors:  Saman Hewamana; Chris Pepper; Steve Couzens; Alun Thomas; Steven Knapper
Journal:  Int J Hematol       Date:  2008-10-11       Impact factor: 2.490

9.  Human immunoglobulin M paraproteins cross-reactive with Neisseria meningitidis group B polysaccharide and fetal brain.

Authors:  F H Azmi; A H Lucas; H L Spiegelberg; D M Granoff
Journal:  Infect Immun       Date:  1995-05       Impact factor: 3.441

10.  IgM monoclonal gammopathy of undetermined significance and smoldering Waldenström's macroglobulinemia.

Authors:  Robert A Kyle; Joanne Benson; Dirk Larson; Terry Therneau; Angela Dispenzieri; L Joseph Melton Iii; S Vincent Rajkumar
Journal:  Clin Lymphoma Myeloma       Date:  2009-03
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.